MAPK1 and metabolic dysfunction-associated steatotic liver disease: Indeed, a recent study reported p38γ and p38δ are selected to be potential therapeutic targets for NAFLD, another study has also reported the use of melatonin in improving NAFLD symptoms in HFD diet mice by modulating p38 pathways.